Dr. Guido Galluzzi is an internationally recognized expert in experimental oncology and translational medicine. He currently leads research initiatives at NeoVita, focusing on understanding and harnessing cell death mechanisms to develop innovative cancer therapies. His work bridges fundamental cancer biology with clinical applications, aiming to translate insights into new treatment strategies that improve patient outcomes.Dr. Galluzzi earned his PhD in Molecular and Cell Biology and has completed extensive postdoctoral training in cancer research, specializing in the molecular pathways that regulate apoptosis, necroptosis, and autophagy. Over the years, he has authored numerous high-impact publications in top-tier journals and contributed to defining how regulated cell death can be manipulated for therapeutic benefit.At NeoVita, Dr. Galluzzi plays a pivotal role in shaping experimental oncology programs, directing translational research that connects laboratory discoveries with clinical trials. His approach integrates mechanistic studies with biomarker-driven patient stratification, aiming to optimize cancer treatment efficacy while minimizing toxicity. Beyond research, he is actively involved in mentoring the next generation of oncologists and scientists and participates in international collaborative initiatives in cancer biology and therapy development.